A joint frailty-copula model for meta-analytic validation of failure time surrogate endpoints in clinical trials
- PMID: 33006170
- DOI: 10.1002/bimj.201900306
A joint frailty-copula model for meta-analytic validation of failure time surrogate endpoints in clinical trials
Abstract
In a meta-analysis framework, the classical approach for the validation of time-to-event surrogate endpoint is based on a two-step analysis. This approach often raises estimation issues. Recently, we proposed a one-step validation approach based on a joint frailty model. This approach was quite time consuming, despite parallel computing, due to individual-level frailties used to take into account heterogeneity in the data at the individual level. We now propose an alternative one-step approach for evaluating surrogacy, using a joint frailty-copula model. The model includes two correlated random effects treatment-by-trial interaction and a shared random effect associated with the baseline risks. At the individual level, the joint survivor functions of time-to-event endpoints are linked using copula functions. We used splines for the baseline hazard functions. We estimated parameters and hazard function using a semiparametric penalized marginal likelihood method, considering various numerical integration methods. Both individual-level and trial-level surrogacy were evaluated using Kendall's tau and coefficient of determination. The performance of the estimators was evaluated using simulation studies. The model was applied to individual patient data meta-analyses in advanced ovarian cancer to assess progression-free survival as a surrogate for overall survival, as part of the evaluation of new therapy. The model showed good performance and was quite robust regarding the integration methods and data variation, regardless of the surrogacy evaluation criteria. Kendall's Tau was better estimated using the Clayton copula model compared to the joint frailty model. The proposed model reduces the convergence and model estimation issues encountered in the two-step approach.
Keywords: joint frailty-copula model; meta-analysis of clinical trials; numerical integration; one-step validation method; surrogate endpoint.
© 2020 Wiley-VCH GmbH.
Similar articles
-
One-step validation method for surrogate endpoints using data from multiple randomized cancer clinical trials with failure-time endpoints.Stat Med. 2019 Jul 20;38(16):2928-2942. doi: 10.1002/sim.8162. Epub 2019 Apr 17. Stat Med. 2019. PMID: 30997685
-
surrosurv: An R package for the evaluation of failure time surrogate endpoints in individual patient data meta-analyses of randomized clinical trials.Comput Methods Programs Biomed. 2018 Mar;155:189-198. doi: 10.1016/j.cmpb.2017.12.005. Epub 2017 Dec 13. Comput Methods Programs Biomed. 2018. PMID: 29512498 Review.
-
Conditional copula models for correlated survival endpoints: Individual patient data meta-analysis of randomized controlled trials.Stat Methods Med Res. 2021 Dec;30(12):2634-2650. doi: 10.1177/09622802211046390. Epub 2021 Oct 9. Stat Methods Med Res. 2021. PMID: 34632882
-
How to use frailtypack for validating failure-time surrogate endpoints using individual patient data from meta-analyses of randomized controlled trials.PLoS One. 2020 Jan 28;15(1):e0228098. doi: 10.1371/journal.pone.0228098. eCollection 2020. PLoS One. 2020. PMID: 31990928 Free PMC article.
-
Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials.Int J Clin Oncol. 2009 Apr;14(2):102-11. doi: 10.1007/s10147-009-0885-4. Epub 2009 Apr 24. Int J Clin Oncol. 2009. PMID: 19390940 Review.
Cited by
-
A novel approach to the analysis of Overall Survival (OS) as response with Progression-Free Interval (PFI) as condition based on the RNA-seq expression data in The Cancer Genome Atlas (TCGA).BMC Bioinformatics. 2024 Sep 13;25(1):300. doi: 10.1186/s12859-024-05897-1. BMC Bioinformatics. 2024. PMID: 39271985 Free PMC article.
-
Surrogate endpoints in mature B-cell neoplasms - meaningful or misleading?Leukemia. 2025 Jan;39(1):25-28. doi: 10.1038/s41375-024-02483-5. Epub 2024 Dec 10. Leukemia. 2025. PMID: 39658627 Free PMC article. Review.
-
End Point Surrogacy in First-Line Chronic Lymphocytic Leukemia.J Clin Oncol. 2025 Feb;43(4):381-391. doi: 10.1200/JCO.24.01192. Epub 2024 Aug 23. J Clin Oncol. 2025. PMID: 39213466 Free PMC article.
-
Surrogacy validation for time-to-event outcomes with illness-death frailty models.Biom J. 2024 Jan;66(1):e2200324. doi: 10.1002/bimj.202200324. Epub 2023 Sep 29. Biom J. 2024. PMID: 37776057 Free PMC article.
-
Dynamic Risk Prediction via a Joint Frailty-Copula Model and IPD Meta-Analysis: Building Web Applications.Entropy (Basel). 2022 Apr 22;24(5):589. doi: 10.3390/e24050589. Entropy (Basel). 2022. PMID: 35626474 Free PMC article.
References
REFERENCES
-
- Abrahantes, J. C., & Burzykowski, T. (2005). A version of the em algorithm for proportional hazard model with random effects. Biometrical Journal, 47, 847-862.
-
- Booth, C. M., & Eisenhauer, E. A. (2012). Progression-free survival: Meaningful or simply measurable? Journal of Clinical Oncology, 30, 1030-1033.
-
- Branchoux, S., Bellera, C., Italiano, A., Rustand, D., Gaudin, A.-F., & Rondeau, V. (2019). Immune-checkpoint inhibitors and candidate surrogate endpoints for overall survival across tumour types: A systematic literature review. Critical Reviews in Oncology/Hematology, 137, 35-42.
-
- Burzykowski, T., & Buyse, M. (2006). Surrogate threshold effect: An alternative measure for meta-analytic surrogate endpoint validation. Pharmaceutical Statistics, 5, 173-186.
-
- Burzykowski, T., Molenberghs, G., Buyse, M., Geys, H., & Renard, D. (2001). Validation of surrogate end points in multiple randomized clinical trials with failure time end points. Journal of the Royal Statistical Society C (Applied Statistics), 50, 405-422.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources